45 reports

MARKET ##.

  • Biological Therapy
  • Cytokine
  • APAC
  • World
  • Company Sales
  • Target

The prominent features of this report are - ##.

  • Blood Disease
  • Chemotherapy
  • Clinical Trial
  • Cytokine
  • World

The primary outcome measure of the trial was to determine the safety and tolerability of repeated doses of NOX-A## alone and in combination with filgrastim in healthy subjects.

  • Cytokine
  • Hospital
  • Targeted Therapy
  • Therapy
  • Juventas Therapeutics, Inc.
  • JAN 09, 2014: NEUMEDICINES TO FEATURE HEMAMAX STUDY RESULTS IN PRESENTATION AT BIOTECH SHOWCASE CONFERENCE
  • interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12 and cytoprotectant erythropoietin.

In the same study, ## consecutive days of treatment with Neupogen® (filgrastim or granulocyte colonystimulating factor [G-CSF]) did not provide any survival benefit versus control.

  • Cytokine
  • Therapy
  • United States
  • Product Initiative
  • Neumedicines Inc.

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Cytokine
  • Leukemia
  • Novartis AG
  • (FILGRASTIM + PLERIXAFOR) - DRUG PROFILE
  • DORMANT PROJECTS, H1 2016

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived...

  • Cytokine
  • HIV AIDS
  • Research And Development
  • Therapy
  • BioLineRx Ltd.

The prominent features of this report are - ##.

  • Blood Disease
  • Cytokine
  • Leukemia
  • United States
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cytokine
  • Lymphoma
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Clinical Trial profile. 141 Trial Title

The prominent features of this report are - ##.

  • Cytokine
  • Therapy
  • World
  • Product Initiative
  • Windtree Therapeutics, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Biological Therapy
  • Cytokine
  • Therapy
  • World
  • Product Initiative
  • Pipeline by Amgen Inc., H1 2016

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Cytokine
  • Monoclonal Antibody
  • Turkey
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cell Therapy
  • Clinical Trial
  • Cytokine
  • Leukemia
  • F. Hoffmann-La Roche Ltd.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## ## UCB SA ## ## ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Q

  • Cell Therapy
  • Clinical Trial
  • Cytokine
  • World
  • GlaxoSmithKline plc

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Conatus Pharmaceuticals Inc ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## Norgine BV ## ## ## ## ## ## ## Otsuka Holdings Co Ltd ## ## ## ## ## ## ## Ocera Therapeutics Inc ##

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Therapy
  • World

Hoffmann-La Roche Ltd ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## Asklepion Pharmaceuticals LLC ## ## ## ## ## ## Altor BioScience Corp ## ## ## ## ## ## Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials a

  • Biological Therapy
  • Cytokine
  • Drug Discovery And Development
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Monoclonal Antibody
  • Neurological Disorder
  • Biogen Idec Inc.

## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## United Kingdom Source: GlobalData' s Phar

  • Blood Disease
  • Cell Therapy
  • Clinical Trial
  • Cytokine
  • Novartis AG

The primary outcome measure of the trial was to determine the safety and tolerability of repeated doses of NOX-A## alone and in combination with filgrastim in healthy subjects.

  • Cancer
  • Cytokine
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cytokine
  • Digestive System Disorder
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.

## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Italy Source: GlobalData' s Pharma Intelligence Center Clinical

  • Clinical Trial
  • Cytokine
  • Drug Discovery And Development
  • Therapy
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Infectious Disease
  • World
  • Product Initiative
  • Clinical Trial profile. 168 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Pharmaceutical
  • World
  • Clinical Trial Profile Snapshots

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cytokine
  • Respiratory Disease
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • Clinical Trial profile. 1081 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Monoclonal Antibody
  • World

The prominent features of this report are - ##.

  • Chronic Disease
  • Clinical Trial
  • Cytokine
  • Pharmaceutical
  • World
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cytokine
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Pharmaceutical
  • World

## ## ## Alfact Innovation ## ## ## ## ## Zhejiang Hisun Pharmaceutical Co., Ltd. ## ## ## ## ## PharmaKing Co., Ltd. ## ## ## ## ## Immuron Limited ## ## ## ## ## Gilead Sciences, Inc. ## ## ## ## ## Genextra S. p. a. ##

  • Cytokine
  • Digestive System Disorder
  • Therapy
  • World
  • Product Initiative

Participants were randomly assigned by a web-based computer system on a ##:##:## model to receive ## milligrams (mg) or ## mg of NGM## or a placebo injection once per day.

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Therapy
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Digestive System Disorder
  • Therapy
  • World